Twenty patients with kloaly advanced or metastatic breast cancer were treated with four cydes of ifosfamide/mesna 5 g m2 and epirubicn 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, F-dgrastim (Tormey et al., 1982; Hortobagyi et al., 1987) . However, the actual differences in dose intensity in these studies were rather minimal. Larg increases in the intensity of conventional chemotherapy are limited by myelosuppression. However, the advent of growth factors into clnical practice has allowed the clinician largely to prevent or ameliorate chemotherapy-induced neutropenia (Bronchud et al., 1987) . Furthermore, it has been possible to use growth factors to accelerate the delivery of chemotherapy and escalate the doses of drugs used. Bronchud et al. (1989) have used granulocyte colony-stimulating factor (G-CSF, Filgrasiim) to inrease both the frequency and dose of doxorubicin delivered to patients with metastatic breast and ovarian cancer. However, this approach is limited by the development of severe muxosal and skin toxicity. In another study using granulocyte-macrophage colony stimulating factor (GM-CSF), Hoek-man et al. (1991) 
chemosensitivity of breast cancer, the disease is never curable once it becomes metastatic (Fey et al., 1981; Paterson et al., 1981) . The median survival of patients with metastatic breast cancer is about 2 years (Clark et al., 1987; Mick et al., 1989) . There is therefore a great need to improve the therapy of metastatic breast cancer in order to make the responses more durable.
Retrospective analysis of the dose of chemotherapy received per unit time (dose intensity) has shown that there has been a good correlation between dose intensity and survival (Hryniuk and Bush, 1984) . This has fuirther been confirmed by two prospective randomised trials. The (Tormey et al., 1982; Hortobagyi et al., 1987) . However, the actual differences in dose intensity in these studies were rather minimal. Larg increases in the intensity of conventional chemotherapy are limited by myelosuppression. However, the advent of growth factors into clnical practice has allowed the clinician largely to prevent or ameliorate chemotherapy-induced neutropenia (Bronchud et al., 1987) . Furthermore, it has been possible to use growth factors to accelerate the delivery of chemotherapy and escalate the doses of drugs used. Bronchud et al. (1989) have used granulocyte colony-stimulating factor (G-CSF, Filgrasiim) to inrease both the frequency and dose of doxorubicin delivered to patients with metastatic breast and ovarian cancer. However, this approach is limited by the development of severe muxosal and skin toxicity. In another study using granulocyte-macrophage colony stimulating factor (GM-CSF), Hoek-man et al. (1991) These results indicate that the combination of ifosfamide and epirubicin given at 14 day intervals with G-CSF is a highly effective regimen for the treatment of metastatic and locally advanced breast cancer. The high objective resonse rate is similar to that found in many other studies using intensive chemotherapy in breast cancer (Antman and Gale, 1988; Bronchud et al., 1989) . The regimen gives as high a response rate as the aceerated doxorubicin regimen of Bronchud et al. (1989) but with much less skin and mucosal toxicity than seen with that regimen. The median duration of remission was fairly short (1.3-20.1 months), and this probably reflects the poor overall prognosis of the group. Additionally, it was clear from the lack of thrombocytopenia experieced that a further escalation of the epirubicin dose might be possible, and this has indeed been planned for a further study with the aim of improving the complete emission rate. In addition to its usefulness as a 'stand-alone' chemotherapy regin in the treatment of metastatic disease, this regimen might also be useful as an induction regimen prior to intensfication with high-dose chemotherapy and either autologous bone marrow or peripheral stem cell transplantation as has been used by other investigators (Dunphy and Spitzer, 1990; 1992; Antman et al., 1992; Eddy, 1992; Eddy et al., 1992) . While the number of patients treated with locally advanced disease was small, all of them responded to treatment, maing the use of this regimen as a neoadjuvant treatment an exciting possibility. It would be interesting to use this regimen more extensively in a neoadjuvant manner as such an approach would appear to be favourable (Scholl et al., 1991) . Additionally, dose int on with an anthracycline-containing regimen appears to improve survival over low-dose therapy (Wood et al., 1994 
